Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity
Severe obesity is a major risk for chronic kidney disease (CKD). Early detection and careful monitoring of renal function are critical for the prevention of CKD during obesity, since biopsies are not performed in patients with CKD and diagnosis is dependent on the assessment of clinical parameters....
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/11/12/836 |
| _version_ | 1797502490179010560 |
|---|---|
| author | Borja Lanzon Marina Martin-Taboada Victor Castro-Alves Rocio Vila-Bedmar Ignacio González de Pablos Daniel Duberg Pilar Gomez Elias Rodriguez Matej Orešič Tuulia Hyötyläinen Enrique Morales Francisco J. Ruperez Gema Medina-Gomez |
| author_facet | Borja Lanzon Marina Martin-Taboada Victor Castro-Alves Rocio Vila-Bedmar Ignacio González de Pablos Daniel Duberg Pilar Gomez Elias Rodriguez Matej Orešič Tuulia Hyötyläinen Enrique Morales Francisco J. Ruperez Gema Medina-Gomez |
| author_sort | Borja Lanzon |
| collection | DOAJ |
| description | Severe obesity is a major risk for chronic kidney disease (CKD). Early detection and careful monitoring of renal function are critical for the prevention of CKD during obesity, since biopsies are not performed in patients with CKD and diagnosis is dependent on the assessment of clinical parameters. To explore whether distinct lipid and metabolic signatures in obesity may signify early stages of pathogenesis toward CKD, liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-high resolution accurate mass-mass spectrometry (GC-HRAM-MS) analyses were performed in the serum and the urine of severely obese patients with and without CKD. Moreover, the impact of bariatric surgery (BS) in lipid and metabolic signature was also studied, through LC-MS and GC-HRAM-MS analyses in the serum and urine of patients with severe obesity and CKD before and after undergoing BS. Regarding patients with severe obesity and CKD compared to severely obese patients without CKD, serum lipidome analysis revealed significant differences in lipid signature. Furthermore, serum metabolomics profile revealed significant changes in specific amino acids, with isoleucine and tyrosine, increased in CKD patients compared with patients without CKD. LC-MS and GC-HRAM-MS analysis in serum of patients with severe obesity and CKD after BS showed downregulation of levels of triglycerides (TGs) and diglycerides (DGs) as well as a decrease in branched-chain amino acid (BCAA), lysine, threonine, proline, and serine. In addition, BS removed most of the correlations in CKD patients against biochemical parameters related to kidney dysfunction. Concerning urine analysis, hippuric acid, valine and glutamine were significantly decreased in urine from CKD patients after surgery. Interestingly, bariatric surgery did not restore all the lipid species, some of them decreased, hence drawing attention to them as potential targets for early diagnosis or therapeutic intervention. Results obtained in this study would justify the use of comprehensive mass spectrometry-based lipidomics to measure other lipids aside from conventional lipid profiles and to validate possible early markers of risk of CKD in patients with severe obesity. |
| first_indexed | 2024-03-10T03:34:49Z |
| format | Article |
| id | doaj.art-05f037bcb00e4696978c287723fdb7ab |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-10T03:34:49Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-05f037bcb00e4696978c287723fdb7ab2023-11-23T09:31:34ZengMDPI AGMetabolites2218-19892021-12-01111283610.3390/metabo11120836Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe ObesityBorja Lanzon0Marina Martin-Taboada1Victor Castro-Alves2Rocio Vila-Bedmar3Ignacio González de Pablos4Daniel Duberg5Pilar Gomez6Elias Rodriguez7Matej Orešič8Tuulia Hyötyläinen9Enrique Morales10Francisco J. Ruperez11Gema Medina-Gomez12LIPOBETA Group, Department Basic Sciences of Health, Faculty of Sciences of Health, Universidad Rey Juan Carlos, 28922 Alcorcón, SpainLIPOBETA Group, Department Basic Sciences of Health, Faculty of Sciences of Health, Universidad Rey Juan Carlos, 28922 Alcorcón, SpainSchool of Science and Technology, Örebro University, 702 81 Örebro, SwedenLIPOBETA Group, Department Basic Sciences of Health, Faculty of Sciences of Health, Universidad Rey Juan Carlos, 28922 Alcorcón, SpainDepartment of Nephrology, University Hospital 12 de Octubre, 28041 Madrid, SpainSchool of Science and Technology, Örebro University, 702 81 Örebro, SwedenDepartment of Surgery, Hospital Universitario 12 de Octubre, 28041 Madrid, SpainDepartment of Surgery, Hospital Universitario 12 de Octubre, 28041 Madrid, SpainSchool of Medical Sciences, Örebro University, 702 81 Örebro, SwedenSchool of Science and Technology, Örebro University, 702 81 Örebro, SwedenDepartment of Nephrology, University Hospital 12 de Octubre, 28041 Madrid, SpainCentro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, 28668 Boadilla del Monte, SpainLIPOBETA Group, Department Basic Sciences of Health, Faculty of Sciences of Health, Universidad Rey Juan Carlos, 28922 Alcorcón, SpainSevere obesity is a major risk for chronic kidney disease (CKD). Early detection and careful monitoring of renal function are critical for the prevention of CKD during obesity, since biopsies are not performed in patients with CKD and diagnosis is dependent on the assessment of clinical parameters. To explore whether distinct lipid and metabolic signatures in obesity may signify early stages of pathogenesis toward CKD, liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-high resolution accurate mass-mass spectrometry (GC-HRAM-MS) analyses were performed in the serum and the urine of severely obese patients with and without CKD. Moreover, the impact of bariatric surgery (BS) in lipid and metabolic signature was also studied, through LC-MS and GC-HRAM-MS analyses in the serum and urine of patients with severe obesity and CKD before and after undergoing BS. Regarding patients with severe obesity and CKD compared to severely obese patients without CKD, serum lipidome analysis revealed significant differences in lipid signature. Furthermore, serum metabolomics profile revealed significant changes in specific amino acids, with isoleucine and tyrosine, increased in CKD patients compared with patients without CKD. LC-MS and GC-HRAM-MS analysis in serum of patients with severe obesity and CKD after BS showed downregulation of levels of triglycerides (TGs) and diglycerides (DGs) as well as a decrease in branched-chain amino acid (BCAA), lysine, threonine, proline, and serine. In addition, BS removed most of the correlations in CKD patients against biochemical parameters related to kidney dysfunction. Concerning urine analysis, hippuric acid, valine and glutamine were significantly decreased in urine from CKD patients after surgery. Interestingly, bariatric surgery did not restore all the lipid species, some of them decreased, hence drawing attention to them as potential targets for early diagnosis or therapeutic intervention. Results obtained in this study would justify the use of comprehensive mass spectrometry-based lipidomics to measure other lipids aside from conventional lipid profiles and to validate possible early markers of risk of CKD in patients with severe obesity.https://www.mdpi.com/2218-1989/11/12/836severe obesityCKDlipidomicsmetabolomicsbariatric surgery |
| spellingShingle | Borja Lanzon Marina Martin-Taboada Victor Castro-Alves Rocio Vila-Bedmar Ignacio González de Pablos Daniel Duberg Pilar Gomez Elias Rodriguez Matej Orešič Tuulia Hyötyläinen Enrique Morales Francisco J. Ruperez Gema Medina-Gomez Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity Metabolites severe obesity CKD lipidomics metabolomics bariatric surgery |
| title | Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity |
| title_full | Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity |
| title_fullStr | Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity |
| title_full_unstemmed | Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity |
| title_short | Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity |
| title_sort | lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity |
| topic | severe obesity CKD lipidomics metabolomics bariatric surgery |
| url | https://www.mdpi.com/2218-1989/11/12/836 |
| work_keys_str_mv | AT borjalanzon lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT marinamartintaboada lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT victorcastroalves lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT rociovilabedmar lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT ignaciogonzalezdepablos lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT danielduberg lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT pilargomez lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT eliasrodriguez lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT matejoresic lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT tuuliahyotylainen lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT enriquemorales lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT franciscojruperez lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity AT gemamedinagomez lipidomicandmetabolomicsignatureofprogressionofchronickidneydiseaseinpatientswithsevereobesity |